The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer

Rohit Malik; Lalit Patel; John R. Prensner; Yang Shi; Matthew K. Iyer; Shruthi Subramaniyan; Alexander Carley; Yashar S. Niknafs; Anirban Sahu; Sumin Han; Teng Ma; Meilan Liu; Irfan A. Asangani; Xiaojun Jing; Xuhong Cao; Saravana M. Dhanasekaran; Dan R. Robinson; Felix Y. Feng; Arul M. Chinnaiyan

doi:10.1158/1541-7786.MCR-14-0257

The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer

Rohit Malik, Lalit Patel, John R. Prensner, Yang Shi, Matthew K. Iyer, Shruthi Subramaniyan, Alexander Carley, Yashar S. Niknafs, Anirban Sahu, Sumin Han, Teng Ma, Meilan Liu, Irfan A. Asangani, Xiaojun Jing, Xuhong Cao, Saravana M. Dhanasekaran, Dan R. Robinson, Felix Y. Feng, Arul M. Chinnaiyan

Research output: Contribution to journal › Article › peer-review

118 Scopus citations

Abstract

Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.

Original language	English (US)
Pages (from-to)	1081-1087
Number of pages	7
Journal	Molecular Cancer Research
Volume	12
Issue number	8
DOIs	https://doi.org/10.1158/1541-7786.MCR-14-0257
State	Published - Aug 2014
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1541-7786.MCR-14-0257

Cite this

Malik, R., Patel, L., Prensner, J. R., Shi, Y., Iyer, M. K., Subramaniyan, S., Carley, A., Niknafs, Y. S., Sahu, A., Han, S., Ma, T., Liu, M., Asangani, I. A., Jing, X., Cao, X., Dhanasekaran, S. M., Robinson, D. R., Feng, F. Y., & Chinnaiyan, A. M. (2014). The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Molecular Cancer Research, 12(8), 1081-1087. https://doi.org/10.1158/1541-7786.MCR-14-0257

Malik, R, Patel, L, Prensner, JR, Shi, Y, Iyer, MK, Subramaniyan, S, Carley, A, Niknafs, YS, Sahu, A, Han, S, Ma, T, Liu, M, Asangani, IA, Jing, X, Cao, X, Dhanasekaran, SM, Robinson, DR, Feng, FY & Chinnaiyan, AM 2014, 'The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer', Molecular Cancer Research, vol. 12, no. 8, pp. 1081-1087. https://doi.org/10.1158/1541-7786.MCR-14-0257

@article{694bd1d2d0e0485ea7b79f0c52a7691a,

title = "The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer",

abstract = "Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.",

author = "Rohit Malik and Lalit Patel and Prensner, {John R.} and Yang Shi and Iyer, {Matthew K.} and Shruthi Subramaniyan and Alexander Carley and Niknafs, {Yashar S.} and Anirban Sahu and Sumin Han and Teng Ma and Meilan Liu and Asangani, {Irfan A.} and Xiaojun Jing and Xuhong Cao and Dhanasekaran, {Saravana M.} and Robinson, {Dan R.} and Feng, {Felix Y.} and Chinnaiyan, {Arul M.}",

year = "2014",

month = aug,

doi = "10.1158/1541-7786.MCR-14-0257",

language = "English (US)",

volume = "12",

pages = "1081--1087",

journal = "Molecular Cancer Research",

issn = "1541-7786",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

TY - JOUR

T1 - The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer

AU - Malik, Rohit

AU - Patel, Lalit

AU - Prensner, John R.

AU - Shi, Yang

AU - Iyer, Matthew K.

AU - Subramaniyan, Shruthi

AU - Carley, Alexander

AU - Niknafs, Yashar S.

AU - Sahu, Anirban

AU - Han, Sumin

AU - Ma, Teng

AU - Liu, Meilan

AU - Asangani, Irfan A.

AU - Jing, Xiaojun

AU - Cao, Xuhong

AU - Dhanasekaran, Saravana M.

AU - Robinson, Dan R.

AU - Feng, Felix Y.

AU - Chinnaiyan, Arul M.

PY - 2014/8

Y1 - 2014/8

N2 - Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.

AB - Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84905962700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905962700&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-14-0257

DO - 10.1158/1541-7786.MCR-14-0257

M3 - Article

C2 - 25030374

AN - SCOPUS:84905962700

SN - 1541-7786

VL - 12

SP - 1081

EP - 1087

JO - Molecular Cancer Research

JF - Molecular Cancer Research

IS - 8

ER -

The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this